

Establishment of a bionetwork for non-invasive, integrative cancer monitoring program

RLA Fellow: Dr. Subhajyoti De, PhD, Associate Professor, Rutgers Cancer Institute of New Jersey

Sponsor: Dr. David J Foran, PhD, Chief Research Informatics Officer, Rutgers Biomedical and Health Sciences

Abstract:

This capstone project will establish an interdisciplinary bionetwork of clinicians, scientists, and patient advocates who share a common goal of facilitating personalized clinical management of patients with gastrointestinal cancer by integrating non-invasive liquid biopsy test data to monitor cancer progression and treatment response at Rutgers Cancer Institute. Successful execution of the capstone project will form the basis for a center for innovative, non-invasive cancer monitoring program at Rutgers.

Primary Stakeholders:

- RBHS Clinicians
- Cancer patients
- Biomedical researchers
- Educators and trainees



Key Steps/Activities:

- Bionetwork Inception
- Leadership and governance structure setup
- Communication and engagement channel setup
- Resources and logistic consideration
- Finalizing evaluation plan and effective measures
- Annual meeting
- Fund-raising and long term sustainability


Effectiveness Measures:

- Diversity, inclusion, and conflict management
- Incorporate feedback from all stakeholders
- Comparative benchmarking against similar program at other cancer centers
- Detailed pivot table and sustainability plan
- Rutgers resources including Canvas for training, and evaluation for trainees
- Workshops, lectures, and networking activities

Communication/Engagement:

- Email group and Team channel
- Bi-weekly meeting via zoom
- Patient advocate talks and panel discussion
- Workshops and trainings
- Annual meeting with all stakeholders

Proposed Timeline:



Current Status/Future Directions:

- **Current status:** Bionetwork is being setup, and communication channels are being laid out for phase-I. The network will be open to all RBHS clinical and basic researchers. We are also discussing with patient advocates in related cancer areas. We are applying for pilot funding for phase-I activities of the bionetwork.
- **Future direction:** We anticipate sustained growth in phase-II, supported by effective leadership, engagement of different stakeholders, and federal funding.